Pharmaceuticals

Our Pharmaceutical business has a broad portfolio of innovative and established medicines. We currently focus on developing new medicines in respiratory and HIV/infectious diseases, oncology and immuno-inflammation; with discovery research exploring these and other areas.

The business generated sales of £16.1 billion in 2016, representing 58% of the total turnover of the Group.

The business is made up of innovative and established medicines and holds leading market positions in respiratory disease and HIV. In our Pharmaceuticals R&D organisation, almost 80% of research spending focuses on two current therapy areas: respiratory and HIV/infectious diseases; and two potential areas: oncology and immuno-inflammation.

Top three sales drivers 2016
Seretide/Advair Respiratory 
Triumeq/Tivicay  HIV
Ellipta portfolio  Repiratory

Our marketplace

The global pharmaceuticals market is vast. The US remains a priority market for growth with other key growth areas including emerging markets and Asia Pacific regions. 

This trend of increasing demand is expected to continue as the world’s population grows, economies in the emerging markets become more prosperous and global changes in lifestyles affect long-term health.

Our strategy

Janet Liberty, a COPD patient in a Philadelphia garden.
Janet Liberty, an COPD patient

Our strategy is to research and produce innovative, high-quality and needed medicines; making these as accessible as possible to countries at all levels of income and development. 

To do this we focus on creating a strong differentiated pipeline, leading in HIV and respiratory, and developing our presence in speciality therapy areas, including oncology and immuno-inflammation. 

Our Pharmaceuticals portfolio

Our portfolio is made up of innovative and established medicines and we have leading global positions in respiratory disease and HIV.

We have been a leader in respiratory disease for over 40 years and have a portfolio of mature products. In recent years, we have strengthened and broadened our respiratory portfolio with the addition of new medicines including an inhaled corticosteroid (ICS) and long-acting beta2 agonist (LABA) combination, a long-acting muscarinic antagonist (LAMA) and LABA dual bronchodilator.

Our HIV business is managed through ViiV Healthcare, a global specialist company in HIV that we majority own, with Pfizer and Shionogi as shareholders. ViiV Healthcare is now a leading global company in HIV and has had significant recent success with regulatory approval and industry leading launches of new medicines. ViiV Healthcare has a number of other antiretroviral medicines in clinical development.

In addition to respiratory and HIV, we have a portfolio of other innovative pharmaceutical products for the treatment of conditions such as lupus, urology and anti-infectives.  

We also have an Established Products Portfolio (EPP) which includes mature medicines in the areas of anti-infectives, allergy, central nervous system, dermatology, respiratory and urology. These products are an important part of our Emerging Markets business where the GSK brand is an important differentiator.

  • £2.6bn

    If we are to continue to discover new medicines and get them to the patients who need them as quickly as possible, we must invest in research. In 2016, £2.6 billion was invested into the search for new pharmaceutical medicines.

The journey to discovering and developing new medicines is lengthy, expensive and subject to a high rate of failure. Learn more about how we discover new medicines

We are exploring different approaches to promote – and speed up – innovation in our labs.  Having broken down the traditional, R&D model, our scientists now work in smaller units focused on specific areas of research. This encourages greater entrepreneurialism and accountability. These groups are tasked with seeking out the biological targets involved in disease and creating molecules or biopharmaceuticals that will ultimately become new medicines. 

We also know that we won’t discover everything inside our own labs and that we need to partner with other companies, academic institutions and research charities.  We currently have research collaborations with more than 1,500 external organisations.

We also recognise our responsibility to meet society’s expectations to invest in disease areas where the science is difficult or where the typical business model to reward innovation may not be relevant; one example being our antibiotics research. We are also one of the few healthcare companies researching the World Health Organization’s three priority diseases - HIV/AIDS, tuberculosis and malaria.